Case #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute

Similar documents
Hematology Case Conference 8/5/03

Hematology 101. Rachid Baz, M.D. 5/16/2014

Smoldering Multiple Myeloma. A Case Study

Multiple Myeloma 101: Understanding Your Labs

Laboratory Examination

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

The ABCs of Waldenström s Macroglobulinemia (WM)

Anaemias and other Pesky Haematology Questions

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance)

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD

Case Study. Accidental Diagnosis of Multiple Myeloma in a 44-Year-Old White Woman due to Erroneous Results via Chemical Analyzers.

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Tracking Disease Status for Multiple Myeloma

Extramedullary Presentation of Biclonal IgGk and IgAk Multiple Myeloma

Common Haematological Problems in Primary Care

Treatment of Relapsed. A Case Study

2013 AAIM Pathology Workshop

Pneumococcemia as the Presenting Feature of Multiple Myeloma

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data

Anemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017

Immunology and the middle ear Andrew Riordan

Test Name Results Units Bio. Ref. Interval

Smoldering Myeloma: Leave them alone!

Criteria for Disease Assessment Joan Bladé

Osteosclerotic Myeloma (POEMS Syndrome)

CASE STUDIES IN CLINICAL APPLICATIONS OF THERAPEUTIC PLASMA EXCHANGE

2016: Plasma Cell Disorders Pre-HCT Data

Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Result Electrophoresis Tests

Plasma Cell Disorders (PCD) Pre-HCT Data

Forms Revision: Myeloma Changes

Lec-14 د.خالد نافع. Medicine. Multiple Myeloma

Autoimmunity in CLL. Anne Silva, MD Hematology Fellows Conference

Problem Based Learning

FAQs- Janet s Inbox. Janet Brunner, PA-C Wed. Feb. 26, 2014 TRAINING & DEVELOPMENT 1.

Autoimmunity and Primary Immune Deficiency

Management of Multiple Myeloma

Supplementary Appendix

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose

Vasishta Tatapudi, M.D. October 23 rd, 2012.

Amyloidosis. James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center. Professor of Medicine Eastern Virginia Medical

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Plasma cell myeloma (multiple myeloma)

CASE REPORT AN UNCOMMON PRESENTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AT DISEASE PROGRESSION. Michael Mian, MD General Hospital of Bolzano

Reports of efficacy and safety studies of primary immunodeficiency

-Heavy Chain Disease Review of 23 Cases

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)

I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015

TYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME

Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Hematology: Challenging Cases with Your Participation COPYRIGHT

SUPPLEMENTARY APPENDIX

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

If unqualified, Complete remission is considered to be Haematological complete remission

Recommendations for Celiac Disease Testing. IgA & ttg IgA

If unqualified, Complete remission is considered to be Haematological complete remission

Primary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg)

Myelomatous Pleural Effusion

88-year-old Female with Lymphadenopathy. Faizi Ali, MD

Multiple myeloma evolves from a clinically silent premalignant

D. Kazmierski, 1 M. L. Palomba, 2 and C. Barsigian Introduction

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

Laboratory diagnosis of plasma proteins and plasma enzymes

Survival and prognostic factors after initiation of treatment in Waldenstrom s macroglobulinemia

Chapter 15 Adaptive, Specific Immunity and Immunization

Multiple Myeloma Early Detection, Diagnosis, and Staging

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias

3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar

PLASMA CELL NEOPLASIA. Michael Miller, MD & Ajaz Shawl, MD

Case Study Discussions on the Nurse s Role in Caring for Patients With Hematologic Malignancies

The Paraprotein. Evaluating Paraproteinemia. Conditions Associated with PP. Paraprotein Structure

Evaluating Paraproteinemia

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

Michael Joffe ST6 Haematology SpR

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain

Study Events 2. Consent Information 3. Family History 5. Registry Visit 8. Visit Information 11. Vitals / Measures 13. Clinical History 15

Case Report Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review

Clinician Blood Panel Results

Patient Identification: Patient Name (first, middle, last)

Case Report Nephrotic Syndrome Secondary to Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits of Lambda Light Chain

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

KJLM. Multiple Myeloma with Biclonal Gammopathy Accompanied by Prostate Cancer INTRODUCTION CASE REPORT. Case Report Diagnostic Hematology

ERROR CORRECTION FORM

Woman, 66, With Persistent Abdominal and Back Pain

Serum Free Light Chain Assay

CIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:

Omar Alnairat. Tamer Barakat. Bahaa Abdelrahim. Dr.Nafez

V. Smoldering multiple myeloma

Separation of Main Proteins in Plasma and Serum

Adaptive Immunity: Specific Defenses of the Host

John Gubatan 1*, Xiaohui Wang 2, Abner Louissaint 3, Anuj Mahindra 4 and John Vanderpool 5

Transcription:

Case #1 Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute

Patient History Part I 76 year-old man 1997 diagnosed with MGUS (biclonal) during evaluation of (self-limited) anemia. Stable. 2002 diagnosed with indolent CD30+ anaplastic large cell lymphoma, managed with topical steroids. 2006 had MRI/CT for evaluation of hip pain. Incidentally found to have retroperitoneal and mesenteric lymphadenopathy. Biopsy. Dx low volume CLL/SLL (nl CBC); tx observation

Patient History Part II Fall 2011 developed dental abscess. -root canal, then dental implant -dental implant infected, then removed -osteomyelitis, treated with prolonged antibiotics -sinus infection -sinus surgery and more antibiotics

ENT follow-up note: On 12/23/11, he underwent removal of left concha bullous, anterior ethmoidectomy, and left maxillary antrostomy; he was given Cleocin- 300 mg. At that time I obtained a culture, the results returning as staphylococcus aureus. I would have liked to start him on doxycyline-100 mg QD but the patient is reluctant to take yet another antibiotic and requests to see an infectious disease specialist.

11/7/2012 Seen in routine follow-up Worst year of my life. Normal physical exam.

CBC (11/7/12) WBC 6.3 RBC 4.45 Hemoglobin 13.7 Hematocrit 40.5 MCV 91.0 Plt 220,000

WBC Differential WBC 6.3 % lymphs 24 %mono 15 (H) %eos 6 %PMN 55 %blast 0

Chemistries CA 9.6 TBILI 1.0 Total Protein 6.9 Albumin 4.4 Globulin 2.5

1. Serum Protein Electrophoresis 2. Quantitative Immune Globulins, (Nephelometry) 3. Immunofixation

1. Serum Protein Electrophoresis: separation of proteins based on charge and molecular weight

Serum Protein Electrophoresis Advantages Useful screening test for monoclonal protein. Able to quantify the size of the M-protein Provides quantitative and pattern information about albumin, alpha-1, alpha-2, beta and gamma globulin Disadvantages When an M-protein is present, SPEP will not be able to provide information about the immunoglobulin heavy and light chain class. Not as sensitive as immunofixation at differentiating monoclonal from polyclonal gammopathy

Serum Protein Electrophoresis Total Protein 6.7 g/dl (6.0-8.0) g/dl Albumin 3.80 g/dl (3.20-5.30) g/dl Alpha 1 0.21 g/dl (0.10-0.40) g/dl Alpha 2 0.82 g/dl (0.50-1.00) g/dl Beta 0.78 g/dl (0.60-1.20) g/dl Gamma 1.08 g/dl (0.80-1.70) g/dl Two M-spikes detected

Immunofixation: after serum electrophoresis, each sample is overlaid with a different mono-specific antibody. Precipitation occurs from formation of antigen-antibody complexes.

Immunofixation More sensitive than serum protein electrophoresis Not quantitative unless done in conjunction with electrophoresis.

Immunofixation Gamma M Spike 1 0.18/g/dL IgM Lambda Gamma M Spike 2 0.62 g/dl IgG Lambda Note units are g/dl

Quantitative Immunoglobulins Most useful test for detecting hypogammaglobulinemia The degree of turbidity produced by antigenantibody reaction is measured by nephelometry ***Does not allow an assessment of clonality

Quantitative Immunoglobulins IgG 942 mg/dl 700-1600 mg/dl IgA 32 mg/dl 70-400 mg/dl IgM 259 mg/dl 40-230 mg/dl

Quantitative immunoglobulins are measured in mg/dl IgG 942 mg/dl 700-1600 mg/dl IgA 32 mg/dl 70-400 mg/dl IgM 259 mg/dl 40-230 mg/dl Gamma M Spike 1 0.18/g/dL IgM Lambda Gamma M Spike 2 0.62 g/dl IgG Lambda Gamma Spikes are measured in g/dl

Calculation of meaningful IgG: 942 mg/dl 700-1600 mg/dl IgA 32 mg/dl 70-400 mg/dl IgM 259 mg/dl 40-230 mg/dl Gamma M Spike 1 0.18/g/dL IgM Lambda Gamma M Spike 2** 0.62 g/dl IgG Lambda Total IgG=942 mg/dl Monoclonal IgG=0.62 g/dl=620 mg/dl Meaningful IgG=942-620=342 mg/dl

Calculation of meaningful IgM: IgG 942 mg/dl 700-1600 mg/dl IgA 32 mg/dl 70-400 mg/dl IgM** 259 mg/dl 40-230 mg/dl Gamma M Spike 1 0.18/g/dL IgM Lambda** Gamma M Spike 2 0.62 g/dl IgG Lambda Total IgM= 258 mg/dl Monoclonal IgM=0.18g/dL=180 mg/dl Meaningful IgM=259-180=79 mg/dl

Diagnosis of our patient Hypogammaglobulinemia in the setting of clonal gammopathy: masked by available clinical laboratory testing.

Treatment Our approach: IVIG or subcutaneous immune globulin in patients with both low Ig and infection. Our patient is receiving IVIG and is doing well so far

Alternative Testing Check baseline immunoglobulin titers against specific common protein and polysaccharide antigens (tetanus, diphtheria, pneumococcus). Immunize Recheck titers in 3 weeks, anticipating a 2-4 fold increase in titers.

Diagnostic Criteria for MGUS M-protein <3 g/l Bone marrow (if done)<10% plasma cells Absence of end organ damage CRAB Hypercalcemia Renal insufficiency Anemia Bone lesions Diagnosis of monoclonal gammopathy of undetermined significance, Robert A. Kyle, in Up to Date 2/2/2013

Monoclonal Gammopathy of Undetermined Significance Patients exhibit no symptoms or physical findings M-protein usually discovered unexpectedly 70% IgG 15% IgM 12% IgA 3% Biclonal Up to 20% may consist only of Ig light chain

NEJM Vol 346, No 8. Feb 21, 2002 P 564-568

NEJM Vol 346, No 8. Feb 21, 2002 P 564-568

The risk of bacteremia in patients with MGUS Danish study: 40 episodes of bacteremia versus 18 episodes expected ~5000 patient-years of follow-up Mean follow-up 3.8 years/patient Swedish study: Two-fold increased risk of bacterial and viral infections in MGUS Eur J Haematol. 1998;Aug 61 (2);140-4 Gregersen H et al Haematologica: 2012:97(6), p854 Kristinsson S et al

Results: 1. Infection rate cut in half 2. Survival rate not altered

Summary 1. We described a gentleman with masked hypogammaglobulinemia in the setting of clonal gammopathy. 2. We describe the interpretation of SPEP, immunofixation, and quantitative immunoglobulins 3. The infection rate is doubled in patients with MGUS. 4. The role of IVIG in MGUS hasn t been well-studied, but in CLL and Myeloma, the rate of infection is reduced by 50% with IVIG but without improvement in overall survival.